WallStSmart

Abbott Laboratories (ABT)vsAdagio Medical Holdings, Inc Common Stock (ADGM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 32356106% more annual revenue ($44.33B vs $137,000). ABT leads profitability with a 14.7% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

ADGM

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -4.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for ADGM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

ADGM2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
75.6%10/10

Revenue surging 75.6% year-over-year

Debt/EquityHealth
-16.7410/10

Conservative balance sheet, low leverage

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ADGM4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$23.93M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : ADGM

The strongest argument for ADGM centers on Revenue Growth, Debt/Equity. Revenue growth of 75.6% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : ADGM

The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while ADGM is a hypergrowth play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.74 — expect wider price swings.

ADGM is growing revenue faster at 75.6% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Adagio Medical Holdings, Inc Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Adagio Medical Holdings, Inc. is a pioneering biotech firm specializing in advanced medical technologies tailored for the treatment of cardiac arrhythmias. Through its proprietary platform, the company is innovating targeted ablation techniques that address critical needs within the electrophysiology market. With a robust product pipeline and a seasoned leadership team, Adagio presents an attractive opportunity for institutional investors aiming to engage in the evolving landscape of healthcare innovation and improve patient outcomes in the cardiac sector.

Visit Website →

Want to dig deeper into these stocks?